JPRN-UMIN000033062已完成2 期
Phase II study of DFP-14323 with low dose EGFR-TKI for EGFR mutation positive NSCLC. - Phase II study of DFP-14323
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients without 1) Contraindicated cases for Erlotinib or Afatinib or Osimertinib 2) Obvious infections 3) T790M, exon20 ins 4) Severe heart diseases 5) Severe complications 6) Brain metasitases 7) Severe digestive diseases 8) Severe thromboembolisms 9) Severe diarrhea 10) Severe psychosis
研究者
相似试验
已完成
不适用
Clinical study of a combined use of EGFR-TKI and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer.non-small cell lung cancerJPRN-UMIN000001966Juntendo University, School of Medicine10
已完成
2 期
Multicenter phase II trial of continuous EGFR-TKIs for elderly patients with EGFR sensitive mutation who failed the first EGFR-TKIs treatment for advanced non-small cell lung cancer.JPRN-UMIN000008027ung Oncology Group in Kyushu, Japan (LOGIK)70
终止
1 期
A Phase 1/2 study to determine the effect of Doxorubicin loaded EnGeneIC Delivery Vehicles on progression free survival in Patients with Recurrent Glioblastoma Multiforme (GBM)Recurrent Glioblastoma MultiformeCancer - BrainACTRN12613000297729EnGeneIC Ltd46
已完成
不适用
Phase II study of EGFR-TKI rechallenge with afatinib in advanced NSCLC patients haboring sensitive EGFR mutation without T790MJPRN-UMIN000015568Okayama University Hospital12
终止
1 期
A study of EnGeneIC Dream Vectors (EDV's) packaged with the chemotherapy, E-EDV-D682 given simultaneously as non-targeted EDVs carrying an immune enhancer called EDV-GC, in participants with advanced pancreatic and other cancers whose disease has progressed after one or two treatment regimes, or where other standard therapies are not appropriate.Advanced Cancer (Solid Tumours)Cancer - PancreaticCancer - Any cancerPancreatic CancerACTRN12619000385145EnGeneIC Pty Limited53